|
- Illumina | Sequencing and array solutions to fuel genomic discoveries
Illumina sequencing and array technologies drive advances in life science research, translational and consumer genomics, and molecular diagnostics
- Has Illumina’s Recent Rebound Created a Long Term Opportunity in 2025?
If you are looking at Illumina and wondering whether today’s price really reflects its long term potential, you are not alone; this stock has gone from market darling to question mark and back
- Illumina (ILMN) Moves to Strong Buy: Rationale Behind the Upgrade - MSN
Illumina (ILMN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy) This rating change essentially reflects an upward trend in earnings estimates -- one
- Illumina, Other Genomics Fims Ramp Up Data Offerings for Pharma, With . . .
NEW YORK – Illumina has long been content to supply as many sequencing reagents as the pharmaceutical industry could handle, but now the firm is willing to offer a more refined product: data Under plans for its new BioInsight business unit, announced in October, Illumina is willing to shoulder the burden of certain sequencing-intensive projects of interest to pharma, such as single-cell
- Invesco Ltd. Buys 444,543 Shares of Illumina, Inc. $ILMN - MarketBeat
Invesco Ltd lifted its stake in Illumina, Inc (NASDAQ:ILMN - Free Report) by 48 9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission The institutional investor owned 1,353,077 shares of the life sciences company's stock after acquiring an additional 444,543 shares during the period Invesco Ltd owned 0 88% of Illumina worth
- Statement Regarding Illumina’s Decision to Divest Grail
Illumina’s decision to unwind its acquisition of Grail ensures the market for cancer detection tests remains competitive and delivers a choice of high-quality tests for patients and physicians, ultimately saving lives
- Illumina (ILMN) Moves to Strong Buy: Rationale Behind the Upgrade
Illumina (ILMN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects This might drive the stock higher in the near term
- Zacks. com featured highlights include Illumina, Commercial Metals and . . .
Illumina, Commercial Metals and Newmont stand out as brokers boost ratings amid inflation concerns and shifting economic signals
|
|
|